公开(公告)号：EP2726869A4

公开(公告)日：2015-03-11

申请号：EP12804757

申请日：2012-06-28

申请人： UNIV DUKE ,  UNIV JOHNS HOPKINS

发明人： YAN HAI ,  BIGNER DARELL ,  VOGELSTEIN BERT ,  KINZLER KENNETH W ,  MEEKER ALAN ,  HRUBAN RALPH ,  PAPADAPOULOS NICKOLAS ,  DIAZ LUIS ,  JIAO YUCHEN

IPC分类号： G01N33/53 ,  A61K31/7105 ,  A61K39/00 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C07K16/40 ,  C12N15/1137 ,  C12Q2600/118 ,  C12Q2600/156 ,  G01N33/57407

摘要： We determined the sequence of ATRX and DAXX in 447 cancers from various sites. We found mutations most commonly in pediatric glioblastoma multiformae (GBM) (11.1%), adult GBM (6.5%), oligodendrogliomas (7.7%) and medulloblastomas (1.5%); and showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism found in cancers that have not activated telomerase, perfectly correlated with somatic mutations of either gene. In contrast, neuroblastomas, and adenocarcinomas of the ovary, breast, and pancreas were negative for mutations in ATRX and DAXX. Alterations in ATRX or DAXX define a specific molecular pathway that is closely associated with an alternative telomere maintenance function in human cancers.

公开(公告)号：EP2780473A4

公开(公告)日：2016-02-17

申请号：EP12849091

申请日：2012-11-12

申请人： UNIV JOHNS HOPKINS

发明人： VOGELSTEIN BERT ,  KINZLER KENNETH W ,  PAPADOPOULOS NICKOLAS ,  WU JIAN ,  HRUBAN RALPH ,  MAITRA ANIRBAN ,  DAL MOLIN MARCO

IPC分类号： C12Q1/68 ,  C12N15/11

CPC分类号： C12Q1/6886 ,  C12Q1/6883 ,  C12Q2600/156

公开(公告)号：EP2417268A4

公开(公告)日：2012-07-11

申请号：EP10749365

申请日：2010-03-05

申请人： UNIV JOHNS HOPKINS

发明人： VOGELSTEIN BERT ,  KINZLER KENNETH W ,  PARSONS D WILLIAMS ,  JONES SIAN ,  KERN SCOTT ,  HRUBAN RALPH ,  ESHLEMAN JAMES R ,  GOGGINS MICHAEL ,  KLEIN ALISON ,  HIDALGO MANUEL ,  VELCULESCU VICTOR E

IPC分类号： C12Q1/68 ,  G01N33/574 ,  G01N33/68

CPC分类号： C12Q1/6886 ,  A61K31/407 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57438 ,  G01N2333/47

公开(公告)号：EP2326734A4

公开(公告)日：2012-07-11

申请号：EP09812193

申请日：2009-09-03

申请人： UNIV JOHNS HOPKINS

发明人： VOGELSTEIN BERT ,  KINZLER KENNETH W ,  PARSONS DONALD WILLIAM ,  JONES SIAN ,  ZHANG XIAOSONG ,  LIN JIMMY CHANG-HO ,  LEARY REBECCA J ,  ANGENENDT PHILIPP ,  PAPADOPOULOS NICKOLAS ,  VELCULESCU VICTOR ,  PARMIGIANI GIOVANNI ,  KARCHIN RACHEL ,  KERN SCOTT ,  HRUBAN RALPH ,  ESHLEMAN JAMES R ,  GOGGINS MICHAEL ,  KLEIN ALISON

IPC分类号： C12Q1/68

CPC分类号： G01N33/57438 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N2800/50

公开(公告)号：EP2723896A4

公开(公告)日：2015-02-18

申请号：EP12802288

申请日：2012-06-22

申请人： UNIV JOHNS HOPKINS

发明人： VOGELSTEIN BERT ,  KINZLER KENNETH W ,  WU JIAN ,  DIAZ LUIS ,  PAPADOPOULOS NICKOLAS ,  MATTHAEI HANNO ,  HRUBAN RALPH ,  MAITRA ANIRBAN

IPC分类号： C12Q1/68 ,  C12N15/11

CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/156

摘要： To help reveal the pathogenesis of these lesions, we purified the DNA from Intraductal Papillary Mucinous Neoplasm (IPMN) cyst fluids from 19 patients and searched for mutations in 169 genes commonly altered in human cancers. We identified recurrent mutations at codon 201 of GNAS. We found that GNAS mutations were present in 66% of IPMNs and that either KRAS or GNAS mutations could be identified in 96%. In eight cases, we could investigate invasive adenocarcinomas that developed in association with IPMNs containing GNAS mutations. In seven of these eight cases, the GNAS mutations present in the IPMNs were also found in the invasive lesion. GNAS mutations were not found in other types of cystic neoplasms of the pancreas or in invasive adenocarcinomas not associated with IPMNs. These data suggest that GNAS mutations can inform the diagnosis and management of patients with cystic pancreatic lesions.

公开(公告)号：EP1575500A4

公开(公告)日：2007-01-03

申请号：EP03764462

申请日：2003-07-14

申请人： UNIV JOHNS HOPKINS

发明人： JAFFEE ELIZABETH ,  WU TZYY-CHOOU ,  HUNG CHIEN-FU ,  HRUBAN RALPH

IPC分类号： A61K39/00 ,  C07K14/47 ,  C07K16/30 ,  G01N33/574

CPC分类号： A61K39/0011 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/6031

摘要： Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.